Peptide Hormone Or Derivative Utilizing Patents (Class 514/5.3)
-
Publication number: 20140349922Abstract: Pegylated and reverse pegylated GLP-1/Glucaron receptor agonists including pharmaceutical compositions comprising the same and methods of using the same are disclosed.Type: ApplicationFiled: June 4, 2012Publication date: November 27, 2014Inventors: Udi Eyal Fima, Oren Hershkóvitz
-
Publication number: 20140349923Abstract: Compositions are disclosed which comprise one or more of the following; an anthocyanin, an oligosaccharide, a pectin, or a long-chain fatty acid. Such compositions are useful for treating diabetes or obesity.Type: ApplicationFiled: January 14, 2013Publication date: November 27, 2014Inventors: Mark Andrew Paulik, Rebecca Jane Hodge
-
Patent number: 8895503Abstract: A method for nasal administration of a pharmaceutical composition comprising a hydrophilic bioactive substance and any one of (a) to (c): (a) a peptide having the amino acid sequence shown in SEQ ID NO:1; (b) a peptide having the same amino acid sequence as shown in SEQ ID NO:1 except that one or several amino acids are deleted, substituted and/or added, the peptide having nasal mucosal permeability; (c) a peptide having an amino acid sequence represented by the reverse sequence of (a) or (b), the peptide having nasal mucosal permeability, with the proviso that a C-terminal amidated peptide is excluded. A hydrophilic bioactive substance having a low transmucosal absorption capability which has conventionally been able to be administered by only injection can be nasally administered. Such a pharmaceutical composition is useful for improvement of the pain and the inconvenience of patients caused by administration by injection.Type: GrantFiled: February 27, 2009Date of Patent: November 25, 2014Assignee: Toray Industries, Inc.Inventors: Mariko Morishita, Kozo Takayama, Reiji Nishio, Nobuo Ida
-
Publication number: 20140336109Abstract: A method and a composition for decreasing ghrelin levels and/or decreasing ghrelin/unacylated ghrelin ratio in a subject, the method comprising administering an effective amount of unacylated ghrelin, a fragment thereof, an analog thereof and/or pharmaceutically acceptable salts thereof to the subject wherein a reduction in ghrelin levels and/or a reduction in ghrelin/unacylated ghrelin ratio is beneficial to the subject. Also, use of ghrelin level and/or ghrelin/unacylated ghrelin ratio as biomarkers for determining a subject's likelihood of responding to and/or benefiting from administration of unacylated ghrelin.Type: ApplicationFiled: December 14, 2012Publication date: November 13, 2014Applicant: Alize Pharma SASInventors: Aart Jan Van Der Lely, Thierry Abribat
-
Publication number: 20140336107Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.Type: ApplicationFiled: November 2, 2012Publication date: November 13, 2014Inventors: Jakob Lind Tolborg, Trine Neerup, Keid Fosgerau, Torben Østerlund, Dorthe Lennert Christensen Almholt, Lone Frost Larsen
-
Patent number: 8883721Abstract: The invention provides methods for treatment, prevention or management of obesity, obesity related disorders, diabetes mellitus, and metabolic syndrome in a subject by administering a ghrelin O-acyltransferase (GOAT) inhibitor and/or a ghrelin receptor antagonist to the subject. The invention also provides ghrelin receptor antagonists of formula (VII): A11-A12-A13-Gly-Ser-A14-Phe-Leu-A15-A16-A17-A18 (SEQ ID NO: 93), wherein each of A11, A12, and A13 is independently absent, an amino acid, or an amino protecting group; each of A15, A16, A17, and A18 is independently absent or an amino acid; and A14 is a serine conjugated with a —(O)C1-C20alky or a diaminopropionic acid conjugated with a —C(O)C1-C20alkyl group, provided that at least one of A11, A12, or A13 is present.Type: GrantFiled: May 12, 2010Date of Patent: November 11, 2014Assignees: McGill University, The Administrators of the Tulane Educational FundInventors: Cyril Y. Bowers, David H. Coy, Simon J. Hocart, Gloria S. Tannenbaum
-
Publication number: 20140329743Abstract: A method of treating a disorder in a subject. The method comprises administering to said subject an effective amount of an agonist of the melanocortin-4 receptor (MC4R). The subject is a heterozygous carrier of an MC4R mutation, and the disorder results from an attenuated response of MC4R to a-melanocortin stimulating hormone (a-MSH).Type: ApplicationFiled: December 28, 2012Publication date: November 6, 2014Inventors: Louis A. Tartaglia, Bart Henderson
-
Publication number: 20140323397Abstract: The present invention provides new uroguanylin derivatives that are useful for the treatment of gastrointestinal disorders. The present invention also provides compositions and methods of treating gastrointestinal disorders and pharmaceutical compositions for accomplishing the same. In some embodiments, these pharmaceutical compositions include oral dosage forms.Type: ApplicationFiled: May 11, 2012Publication date: October 30, 2014Applicant: Ironwood Pharmaceuticals, incInventors: Mark G. Currie, Daniel P. Zimmer, Marco Kessler
-
Patent number: 8871706Abstract: The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogous of native hGhrelin.Type: GrantFiled: August 7, 2008Date of Patent: October 28, 2014Assignee: Ipsen Pharma S.A.S.Inventors: Zheng Xin Dong, Michael DeWitt Culler, Rakesh Datta, John E. Taylor
-
Publication number: 20140286931Abstract: The present invention relates to new biphenyl-3-carboxylic acid modulators of beta-3-adrenoceptor activity, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: June 5, 2014Publication date: September 25, 2014Inventor: Chengzhi Zhang
-
Publication number: 20140256621Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.Type: ApplicationFiled: July 3, 2012Publication date: September 11, 2014Inventors: Mary Erickson, David C. Litzinger, Soumitra S. Ghosh, Zijian Guo, Caroline Ekbland, Jonathan David Roth
-
Publication number: 20140249077Abstract: The present invention is directed to compositions and methods of preparation of phospholipid gels.Type: ApplicationFiled: June 8, 2012Publication date: September 4, 2014Applicants: ASTRAZENECA PHARMACEUTICALS LP, AMYLIN PHARMACEUTICALS, LLCInventors: Andrew Xian Chen, Hailiang Chen
-
Patent number: 8822413Abstract: A bifunctional hormone exhibiting an alpha-MSH activity and a natriuretic peptide activity is described. The bifunctional hormone comprises for example a first domain having alpha-MSH related hormonal activity covalently linked to a second domain having natriuretic peptide related hormonal activity. The bifunctional hormone of the present invention is useful for example for the prevention and/or treatment of renal related diseases or conditions, such as acute renal failure (ARF) or acute kidney injury (AKI).Type: GrantFiled: July 7, 2008Date of Patent: September 2, 2014Assignee: Theratechnologies Inc.Inventors: Krishna G. Peri, Abdelkrim Habi
-
Publication number: 20140243260Abstract: The present invention relates to an isolated chimeric protein. The isolated chimeric protein includes an N-terminus coupled to a C-terminus, where the N-terminus includes an N-terminal portion from a fibroblast growth factor (“FGF”) 23 molecule and the C-terminus includes a C-terminal portion from an FGF19 molecule. The present invention also relates to a pharmaceutical composition including an isolated chimeric protein and a pharmaceutically acceptable carrier. The isolated chimeric protein includes an N-terminus coupled to a C-terminus, where the N-terminus includes an N-terminal portion from a fibroblast growth factor (“FGF”) 23 molecule and the C-terminus includes a C-terminal portion from an FGF19 molecule, and a pharmaceutically-acceptable carrier. Yet another aspect of the present invention relates to a method for treating a subject suffering from a disorder.Type: ApplicationFiled: February 20, 2014Publication date: August 28, 2014Applicant: NEW YORK UNIVERSITYInventors: Moosa MOHAMMADI, Regina GOETZ
-
Publication number: 20140235535Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration, and reduced immunogenicity. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, Short Bowel Syndrome, Parkinson's disease, and cardiovascular disease.Type: ApplicationFiled: July 3, 2012Publication date: August 21, 2014Inventors: Mary Erickson, David C. Litzinger, Soumitra S. Ghosh, Zijian Guo, Manoj P. Samant, Abhinandini Sharma, Lala Mamedova, Esther Odile Levy, Caroline Ekblad
-
SUBSTITUTED QUINAZOLINES, THE PREPARATION THEREOF AND THE USE THEREOF IN PHARMACEUTICAL COMPOSITIONS
Publication number: 20140228283Abstract: The present invention relates to substituted quinazolines of formula (I) wherein X and Y are defined as in claim 1, the tautomers, stereoisomers, mixtures and salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-W (DPP-IV).Type: ApplicationFiled: July 13, 2012Publication date: August 14, 2014Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Waldemar Pfrengle, Markus Frank, Thomas Klein -
Publication number: 20140228284Abstract: The present invention provides pharmaceutical compositions comprising at least one polypeptide having GLP-1 activity wherein an effective dose of said pharmaceutical composition comprises 15 mg, 30 mg, 50 mg or 100 mg of said polypeptide having GLP-1 activity. Also provided are methods of administering the pharmaceutical compositions of the invention.Type: ApplicationFiled: April 25, 2014Publication date: August 14, 2014Applicant: GlaxoSmithKline, LLCInventors: Mark A. BUSH, Murray W. Stewart, Yonghong Yang
-
Publication number: 20140221281Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.Type: ApplicationFiled: December 20, 2013Publication date: August 7, 2014Applicant: SanofiInventors: Torsten HAACK, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Andreas Evers, Martin Lorenz, Katrin Lorenz
-
Publication number: 20140221282Abstract: There are provided compounds having two peptide hormones bound to a central water-soluble polymeric spacer and methods of use thereof.Type: ApplicationFiled: May 24, 2012Publication date: August 7, 2014Inventors: Chengzao Sun, Behrouz Bruce Forood
-
Publication number: 20140221280Abstract: Peptide containing sequence from both the GLP-1 peptide and glucagon peptide, compositions comprising said peptides and methods of using said peptides for the treatment and prevention of metabolic disorders, for example disorders of energy metabolism such as obesity or diabetes, are providedType: ApplicationFiled: July 4, 2011Publication date: August 7, 2014Applicant: IMPERIAL INNOVATIONS LIMITEDInventor: Stephen Robert Bloom
-
Publication number: 20140221283Abstract: Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.Type: ApplicationFiled: June 12, 2012Publication date: August 7, 2014Applicant: Indiana University Research and Technology CorporationInventors: Richard D. Dimarchi, David L. Smiley
-
Publication number: 20140212472Abstract: Methods of treating obesity, metabolic syndrome, hepatic and non-hepatic steatosis, and diabetes using a pentapeptide, LVKGRamide, derived from the C-terminus of Glucagon-Like Peptide 1 (GLP-1).Type: ApplicationFiled: July 5, 2012Publication date: July 31, 2014Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Joel F. Habener, Eva Tomas-Falco
-
Publication number: 20140213513Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.Type: ApplicationFiled: December 20, 2013Publication date: July 31, 2014Applicant: SanofiInventors: Torsten Haack, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Andreas Evers, Martin Lorenz, Katrin Lorenz
-
Publication number: 20140206607Abstract: Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.Type: ApplicationFiled: June 12, 2012Publication date: July 24, 2014Applicant: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATIONInventors: Richard D. Dimarchi, David L. Smiley, Bin S. Yang
-
Publication number: 20140206608Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.Type: ApplicationFiled: December 20, 2013Publication date: July 24, 2014Applicant: SanofiInventors: Torsten Haack, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Andreas Evers, Martin Lorenz, Katrin Lorenz
-
Publication number: 20140206609Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.Type: ApplicationFiled: December 20, 2013Publication date: July 24, 2014Applicant: SanofiInventors: Torsten Haack, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Andreas Evers, Martin Lorenz, Katrin Lorenz
-
Patent number: 8779103Abstract: The present invention relates to drug fusions that have improved serum half lives. These fusions and conjugates comprise polypeptides, immunoglobulin (antibody) single variable domains and GLP and/or exendin molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates.Type: GrantFiled: March 24, 2010Date of Patent: July 15, 2014Assignee: Glaxo Group LimitedInventors: Christopher Herring, Lucy J. Holt, Laurent S. Jespers, Sebastian Mayer, Malgorzata Pupecka-Swider
-
Patent number: 8778872Abstract: Prodrug formulations of glucagon superfamily peptides are provided wherein the glucagon superfamily peptide has been modified by the linkage of a dipeptide to the glucagon superfamily through an amide bond linkage. The prodrugs disclosed herein have extended half lives and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.Type: GrantFiled: June 14, 2011Date of Patent: July 15, 2014Assignee: Indiana University Research and Technology CorporationInventors: Richard D. DiMarchi, Binbin Kou
-
Publication number: 20140162945Abstract: The present invention provides a GIP analog, which is derived from GIP (1-29, SEQ ID NO: 1), has both GLP-1 agonist activity and GIPR stimulation activity, and comprises an amino acid sequence represented by the following formula I: Tyr-A2-A3-Gly-Thr-Phe-A7-Ser-Asp-Tyr-Ser-A12-A13-A14-A15-Lys-A17-A18-A19-A20-A21-A22-A23-A24-Trp-Leu-A27-A28-A29-Y. The present invention also provides a pharmaceutical composition comprising the GIP analog and use thereof.Type: ApplicationFiled: June 8, 2012Publication date: June 12, 2014Applicant: BEIJING HANMI PHARMACEUTICAL CO., LTD.Inventors: Tao Ma, Shusen Xu, Zhijun Liu, Bo Zhang, Ning Shen, Hai Yang, Wei Zhang, Yuhua Li, Sunghwan Moon, Maengsup Kim
-
Publication number: 20140162944Abstract: The present invention relates to compositions forming a low viscosity mixture of: a) 20-80 wt. % of at least one diacyl glycerol and/or a tocopherol; b) 20-80 wt. % of at least one phosphatidyl choline (PC); c) 5-20 wt. % of at least one biocompatible, organic mono-alcoholic solvent; d) up to 20 wt. % polar solvent e) at least one peptide active agent; f) optionally at least one antioxidant; wherein the ratio of components a:b is in the range 40:60 to 54:46; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations.Type: ApplicationFiled: May 25, 2012Publication date: June 12, 2014Applicant: CAMURUS ABInventors: Fredrik Tiberg, Catalin Nistor, Markus Johnsson
-
Publication number: 20140162946Abstract: Formulations and methods for weight loss and body contouring are disclosed. An illustrative formulation comprises human chorionic gonadotrophin (hCG) and resveratrol. An illustrative method for weight loss and body contouring comprises administering hCG and resveratrol sublingually.Type: ApplicationFiled: February 13, 2014Publication date: June 12, 2014Applicant: Red Mountain Med Spa, LLCInventors: Mark Bentz, Suzanne Bentz, Riccardo Roscetti, M. Socorro Parra Arenas
-
Patent number: 8748375Abstract: Methods for affecting body composition include the use of amylin agonists, such as pramlintide or davalintide. Total body weight may be reduced, maintained or even increased; however, the body fat is reduced or body fat gain is prevented, while lean body mass is maintained or increased.Type: GrantFiled: March 17, 2010Date of Patent: June 10, 2014Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Christine M. Mack, Jonathan David Roth
-
Patent number: 8748377Abstract: The present invention provides pharmaceutical compositions comprising at least one polypeptide having GLP-1 activity wherein an effective dose of said pharmaceutical composition comprises 15 mg, 30 mg, 50 mg or 100 mg of said polypeptide having GLP-1 activity. Also provided are methods of administering the pharmaceutical compositions of the invention.Type: GrantFiled: December 10, 2009Date of Patent: June 10, 2014Assignee: GlaxoSmithKline LLCInventors: Mark A. Bush, Murray W. Stewart, Yonghong Yang
-
Publication number: 20140154214Abstract: GLP-2 analogues are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an increased small intestine/colon and stomach/colon selectivity. More particularly, preferred GLP-2 analogues disclosed herein comprise substitutions at one or more of positions 11, 16, 20, 24 and/or 28 of the wild-type GLP-2 sequence, optionally in combination with further substitutions at position 2 and one or more of positions 3, 5, 7, and 10, and/or a deletion of one or more of amino acids 31 to 33 and/or the addition of a N-terminal or C-terminal stabilizing peptide sequence. The analogues are particularly useful for the prophylaxis or treatment of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy.Type: ApplicationFiled: February 4, 2014Publication date: June 5, 2014Inventors: Bjarne Due LARSEN, Yvette Miata Petersen
-
Patent number: 8741836Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.Type: GrantFiled: June 8, 2012Date of Patent: June 3, 2014Assignee: Novo Nordisk A/SInventors: Lauge Schaeffer, Thomas Kruse, Henning Thoegersen
-
Publication number: 20140148383Abstract: Obesity is inhibited by administering to a person in need thereof an effective amount of entacapone ((2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide), or a pharmaceutically-acceptable salt thereof, particularly in conjunction with a second, different anti-obesity medicament. Pharmaceutical compositions comprise entacapone copackaged or coformulated with a second, different anti-obesity medicament.Type: ApplicationFiled: January 4, 2014Publication date: May 29, 2014Applicant: NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJINGInventors: Niu Huang, Gang Zhi, Jijie Chai, Shiming Peng, Nannan Hou
-
Patent number: 8729011Abstract: Prodrug formulations of glucagon superfamily peptides are provided wherein the glucagon superfamily peptide has been modified by the linkage of a dipeptide to the glucagon superfamily through an amide bond linkage. The prodrugs disclosed herein have extended half lives and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.Type: GrantFiled: June 14, 2011Date of Patent: May 20, 2014Assignee: Indiana University Research and Technology CorporationInventors: Richard D. DiMarchi, Binbin Kou
-
Publication number: 20140121154Abstract: This invention relates to novel compositions comprising analogs of glucagon, wherein the analog comprises an ?-amino acid and at least one ?-amino acid. Administration of the compositions may be used for effecting treatment or prevention of a plurality of disease states caused by dysfunctional biochemical or biological pathways, including diabetes and other metabolic disorders. The compositions and methods of this invention are particularly useful to identify novel therapeutic modulators of in-vivo receptor activity with extended half-lives and relevant bioactivity as compared to the naturally translated polypeptides upon which the analogs are derived.Type: ApplicationFiled: April 5, 2012Publication date: May 1, 2014Applicant: Longevity Biotech, Inc.Inventors: Scott Shandler, Samuel H. Gellman
-
Publication number: 20140121155Abstract: Physical crystal structures of a compound of the formula I: are provided including the free base monohydrate thereof (form H-1) and the hydrochloric acid salt thereof, including hydrochloric acid salt containing 0.75 equivalent of H2O (form H0.75-3) and hydrochloric acid salt containing 2 equivalents of H2O (form H2-1), and hydrochloric acid salt Pattern P-5, preferably in substantially pure form, and other forms as described herein, pharmaceutical compositions containing structures of compound I or IA, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures.Type: ApplicationFiled: December 27, 2013Publication date: May 1, 2014Applicant: Bristol-Myers Squibb CompanyInventors: Jack Z. Gougoutas, Mary F. Malley, John D. DiMarco, Xiaotian S. Yin, Chenkou Wei, Jurong Yu, Truc Chi Vu, Gregory Scott Jones, Scott A. Savage
-
Publication number: 20140107021Abstract: Provided herein are peptide combinations comprising a GIP agonist peptide and a glucagon antagonist peptide. In some embodiments, the peptide combination is provided as a composition, e.g., a pharmaceutical composition, while in other embodiments, the peptide combination is provided as a kit. In yet other embodiments, the peptide combination is provided as a conjugate, e.g., a fusion peptide, a heterodimer. In specific aspects, the GIP agonist peptide is an analog of native human glucagon. In specific aspects, the glucagon antagonist peptide is an analog of native human glucagon. In some embodiments, the GIP agonist peptide is covalently attached to the glucagon antagonist peptide via a linker. Method of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the peptide compositions described herein are further provided.Type: ApplicationFiled: September 13, 2013Publication date: April 17, 2014Applicant: Indiana University Research and Technology CorporationInventors: Richard D. DiMARCHI, Tao MA
-
Publication number: 20140107022Abstract: The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF19 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, and methods of screening for compounds with enhanced binding affinity for the ?Klotho-FGF receptor complex involving the use of chimeric proteins of the present invention.Type: ApplicationFiled: December 4, 2013Publication date: April 17, 2014Applicant: New York UniversityInventors: Moosa MOHAMMADI, Regina GOETZ
-
Publication number: 20140094406Abstract: The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF21 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, and methods of screening for compounds with enhanced binding affinity for the ?Klotho-FGF receptor complex involving the use of chimeric proteins of the present invention.Type: ApplicationFiled: December 4, 2013Publication date: April 3, 2014Applicant: New York UniversityInventors: Moosa MOHAMMADI, Regina GOETZ
-
Publication number: 20140087996Abstract: The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor and a GLP-1 receptor agonist which is suitable in the treatment or prevention of diabetes mellitus, impaired glucose tolerance, hyperglycemia or other conditions. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.Type: ApplicationFiled: December 4, 2013Publication date: March 27, 2014Applicant: Boehringer Ingelheim International GmbHInventors: Thomas KLEIN, Rolf GREMPLER, Michael MARK
-
Publication number: 20140073563Abstract: The invention is directed to a fusion protein comprising at least one FGF-21 (fibroblast growth factor-21) compound and at least one GLP-1R (glucagon-like peptide-1 receptor) agonist as well as to pharmaceutical compositions, medical uses and methods of treatment involving the fusion protein, particularly in the field of diabetes, dyslipidemia, obesity and/or adipositas.Type: ApplicationFiled: September 6, 2013Publication date: March 13, 2014Applicant: SANOFIInventors: Oliver BOSCHEINEN, Matthias DREYER, Paul HABERMANN, Hans-Ludwig SCHAEFER, Mark SOMMERFELD, Thomas LANGER
-
Publication number: 20140057839Abstract: Formulations and methods for weight loss and body contouring are disclosed. An illustrative formulation comprises human chorionic gonadotrophin (hCG) and resveratrol. An illustrative method for weight loss and body contouring comprises administering hCG and resveratrol sublingually.Type: ApplicationFiled: August 26, 2013Publication date: February 27, 2014Applicant: Red Mountain Med Spa, LLCInventors: Mark Bentz, Suzanne Bentz, Riccardo Roscetti, M. Socorro Parra Arenas
-
Patent number: 8642541Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: GrantFiled: December 15, 2008Date of Patent: February 4, 2014Assignee: Zealand Pharma A/SInventors: Eddi Meier, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard, Trine Skovlund Ryge Neerup
-
Patent number: 8642540Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metablic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: GrantFiled: December 15, 2008Date of Patent: February 4, 2014Assignee: Zealand Pharma A/SInventors: Eddi Meier, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard
-
Publication number: 20140031278Abstract: The present invention relates to novel glucagon peptides with improved stability and solubility at neutral pH, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The glucagon peptides of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.Type: ApplicationFiled: March 28, 2012Publication date: January 30, 2014Applicant: NOVO NORDISK A/SInventors: Jesper F. Lau, Thomas Kruse, Henning Thoegersen, Thomas Nylandsted Krogh, Ulrich Sensfuss
-
Publication number: 20140018290Abstract: The invention relates to Leptin derivatives, compositions and therapeutic use there-of.Type: ApplicationFiled: January 24, 2012Publication date: January 16, 2014Applicant: Novo Nordisk A/SInventors: Janos Tibor Kodra, Kilian Waldemar Conde-Frieboes, Johan Fredrik Paulsson, Kirsten Raun
-
Publication number: 20140018291Abstract: Methods are provided for administering an extended half-life GLP-1/GIP coagonist peptide to a patient in need thereof for reducing weight gain, inducing weight loss, treating hyperglycemia, reducing blood glucose levels, or normalizing blood glucose levels in said patient.Type: ApplicationFiled: December 22, 2011Publication date: January 16, 2014Applicant: MARCADIA BIOTECH, INC.Inventors: Louis Vignati, Richard D. Dimarchi